



iCo Therapeutics

Amphotericin B is a highly potent, gold standard agent with anti-fungal and anti-parasitic activity. Currently, only intravenous (IV) formulations are approved for use, some of which have IV-related side effects and potentially fatal kidney toxicity. IV treatment is impractical and prohibitively expensive in many disease indications. The latest, least toxic IV Amphotericin, AmBisome[®], is premium priced for improved safety.

In animal models, use of iCo's Oral Amphotericin B Delivery System resulted in blood levels that are comparable to a known IV Amphotericin B product on the market. In fungal and parasitic models, iCo's formulation has shown **significant anti-fungal and anti-parasitic activity with no observable kidney toxicity**. The Oral Amphotericin B Delivery System was invented by Drs. Kishor & Ellen Wasan at the University of British Columbia.

POTENTIAL INDICATIONS

Developed World: Anti-Fungal

Systemic Fungal Infections

Immune-compromised patients: Cancer, HIV/AIDS, Diabetes, Transplantation

Developing World: Anti-Parasitic

Visceral Leishmaniasis

2nd largest parasitic killer after malaria
500,000 new infections every year
Fatal if left untreated

*AmBisome[®]
(Intravenous
formulation of
Amphotericin B)
>\$400M sales in 2009*

PRODUCT HIGHLIGHTS

Lipid-based "candy wrapper"
Expanding the Amphotericin B market: safety and convenience
Oral treatment is a goal of global health organizations including Gates Foundation & World Health Organization
Further non-dilutive funding potential
Proprietary platform may be used for other insoluble products

RECENT & UPCOMING MILESTONES

- ✓ FDA Pre-IND meeting – iCo has a plan to move forward
- ✓ Orphan Drug Status received for Visceral Leishmaniasis
- ✓ Non-dilutive funding received (CPDD/Gates Foundation and CIHR)
- ✓ Robust Scientific Advisory Board assembled
- Phase 1 trial planned for 2012
- Pursuing non-dilutive funding

Oral Amphotericin B Delivery System

SCIENTIFIC ADVISORY BOARD

Dr. Don Buell, Chairman

Formerly Senior Medical Director at Astellas Pharma Inc. Brought multiples anti-fungals to market, including Diflucan[®], Mycamine[®], Prograf[®], AmBisome[®]

Thomas J. Walsh, MD

Director of the Transplantation-Oncology Infectious Diseases Program of Weill Cornell Medical College of Cornell University, New York, NY.

Dr. Coleman Rotstein

Professor of Medicine in the Division of Infectious Diseases at the University of Toronto and Attending Physician at the University Health Network, Toronto, ON.

Dr. Jack Sobel

Associate Chairman for Research, Department of Internal Medicine, Wayne State University, Detroit, MI.

760-777 Hornby St
Vancouver, BC Canada V6Z 1S4
604-602-9414

www.icotherapeutics.com